AB0544 PHENOTYPING ON MUCOSAL MOLECULAR SIGNITURE OF PATIENTS WITH ULCERATIVE COLITIS ANALYSIS

M. R. Chen,Q. Wang,J. W. Hao,M. J. Chang,S. X. Zhang,Q. Yu,P. F. He
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.1190
IF: 27.973
2023-01-01
Annals of the Rheumatic Diseases
Abstract:Background Ulcerative colitis (UC) is an inflammatory bowel disease characterized by idiopathic and recurrent mucosal inflammation, whereas disease heterogeneity has not sufficiently translated into current clinical subclassifications [1]. Objectives This study aims to Identify and characterize subgroups of patients with similar target status and molecular biomarkers to reliably predict treatment response which is of great interest for the treatment of UC patients. Methods 16 microarray datasets including 602 colon tissue samples (455 patients with UC and 147 healthy controls) were both obtained from GEO database. Depend on up-regulated differentially expressed genes (DEGs),unsupervised clustering [2] was applied to group the samples and pathways and biomarkers associated with UC was unearthed by gene-set enrichment analysis. Xgboost classifier was used for evaluating the efficacy of different biologics in patients with UC. Results According to the 267 upregulated DEGs of UC, colon tissue samples were classified into three subtypes(A-C) with distinct molecular and cellular characteristics. Subtype A is designated as epithelial hyperplastic subtype with epithelial features while subtype C was characterized by the immune activation subtype with prominent immune cells and proinflammatory signatures. The subtype B is named mixed, which is in between the above two and is moderately activated in all signaling pathways. It is worth noting that, compared with subtype C as refractory UC patients, subtype A shows stronger correlation with the excellent reactions of biological agents such as golimumab(80%in A vs 37.5%in C), infliximab(100%in A vs 16.7%in C), vedolizumab(33.3%in A vs 0% in C) and ustekinumab(22.4%in A vs 3%in C). Conclusion These results, based on the most comprehensive microarray provide an in-depth understanding of the pathophysiological characteristics of UC, and build an accurate typing model for ulcerative colitis, which can benefit clinical treatment. References [1]Ghosh S, Shand A, Ferguson A. Ulcerative colitis. BMJ (Clinical research ed) 2000;320(7242):1119-23. doi: 10.1136/bmj.320.7242.1119 [published Online First: 2000/04/25] [2]Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. American journal of epidemiology 2013;178(7):1177-84. doi: 10.1093/aje/kwt084 [published Online First: 2013/07/19] Acknowledgements: NIL. Disclosure of Interests None Declared.
What problem does this paper attempt to address?